
    
      Participants include randomization-ineligible (RI) patients from the lead-in double-blind
      trials MCP-103-302 (NCT00938717) or MCP-103-303 (NCT00730015), or rollover (RO) patients from
      the lead-in double-blind trials MCP-103-302 (NCT00938717), MCP-103-303 (NCT00730015), and
      from the Phase 2 double-blind studies MCP-103-004 (NCT00306748), MCP-103-005 (NCT00258193),
      and MCP-103-201 (NCT00402337), or MCP-103-202 (NCT00460811).
    
  